Alumis Inc. (NasdaqGS: ALMS)
Health Care · Pharmaceuticals · US
$23.62
-1.42% today · +394.1% 1Y
Alumis Inc. (NasdaqGS: ALMS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.06B and employs 237 people.
Over the last twelve months the share price has gained 394.1%, trading between 3.76 and 31.35.
Tweenvest scores Alumis Inc. across four factors: quality 28/100, value 54/100. Its strongest factor is value.
ALMS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.06B
- Revenue (TTM)
- $7.40M
- P/E
- —
- EPS
- -3.80
- Dividend yield
- —
- Beta (5Y)
- -0.67
- 52-week high
- $31.35
- 52-week low
- $3.76
- Avg volume (3M)
- —
- Shares outstanding
- 129.44M
- Employees
- 237
- Next earnings
- —
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
- ISIN
- US0223071020
- Founded
- 2021
- Listed since
- Jun 28, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.